Published in Neoplasia on April 01, 2010
The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol (2011) 1.54
Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer (2011) 1.14
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Front Oncol (2015) 1.05
Emerging therapeutics targeting mRNA translation. Cold Spring Harb Perspect Biol (2012) 1.04
mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis. Cancer Res (2013) 1.04
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther (2012) 1.02
Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress. J Invest Dermatol (2013) 1.00
mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation. Oncogene (2015) 0.95
Noncytotoxic inhibition of viral infection through eIF4F-independent suppression of translation by 4EGi-1. J Virol (2010) 0.91
Poly(A) binding proteins: are they all created equal? Wiley Interdiscip Rev RNA (2012) 0.90
The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. Br J Cancer (2012) 0.89
Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration. Neoplasia (2012) 0.89
Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth. Cancer Res (2014) 0.88
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. Mol Cancer Ther (2011) 0.87
Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation. Mol Cancer Ther (2012) 0.87
Signalling to eIF4E in cancer. Biochem Soc Trans (2015) 0.86
Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming. Oncotarget (2013) 0.86
Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G. Proc Natl Acad Sci U S A (2014) 0.85
The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition. Cancer Prev Res (Phila) (2012) 0.82
GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget (2015) 0.79
CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway. Oncotarget (2016) 0.79
SUMO-2 promotes mRNA translation by enhancing interaction between eIF4E and eIF4G. PLoS One (2014) 0.78
DED or alive: assembly and regulation of the death effector domain complexes. Cell Death Dis (2015) 0.77
The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206. Cell Cycle (2015) 0.75
An eIF4E-interacting peptide induces cell death in cancer cell lines. Cell Death Dis (2014) 0.75
Dinosaurs and ancient civilizations: reflections on the treatment of cancer. Neoplasia (2010) 0.75
Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress. Oncotarget (2016) 0.75
The interconnectedness of cancer cell signaling. Neoplasia (2011) 0.75
A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. Mol Cancer Res (2017) 0.75
4EGI-1 induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylation. Oncotarget (2016) 0.75
Targeting EIF4F complex in non-small cell lung cancer cells. Oncotarget (2017) 0.75
Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation. Horm Cancer (2017) 0.75
Downregulation of eIF4G by microRNA-503 enhances drug sensitivity of MCF-7/ADR cells through suppressing the expression of ABC transport proteins. Oncol Lett (2017) 0.75
mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86
Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ (2004) 9.96
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature (2005) 6.69
The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 5.18
eIF-4E expression and its role in malignancies and metastases. Oncogene (2004) 5.10
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
eIF4E--from translation to transformation. Oncogene (2004) 3.78
CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem (2004) 3.70
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell (2007) 3.21
Will mTOR inhibitors make it as cancer drugs? Cancer Cell (2003) 3.15
Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res (2008) 3.02
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest (2007) 3.01
Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell (2004) 2.91
cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol (2006) 2.53
FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol (2001) 2.39
The mRNA cap-binding protein eIF4E in post-transcriptional gene expression. Nat Struct Mol Biol (2004) 2.37
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst (2004) 2.13
Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev (2008) 2.08
eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol (1999) 2.08
The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res (2007) 2.06
The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene (1996) 2.04
Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. Mol Cell Biol (2005) 1.99
Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol (2004) 1.99
Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res (1997) 1.96
TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials (2009) 1.73
Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res (1997) 1.70
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene (2006) 1.66
An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem (2002) 1.65
Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene (2005) 1.64
Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev (2008) 1.60
mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol (2005) 1.56
Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem (2005) 1.54
The caspase-8 modulator c-FLIP. Crit Rev Immunol (2005) 1.52
Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res (2005) 1.51
Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res (2008) 1.46
Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol (2005) 1.44
c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res (2007) 1.43
Targeting death-inducing receptors in cancer therapy. Oncogene (2007) 1.42
Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol Cell Biol (2002) 1.42
Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther (2007) 1.41
Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene (1999) 1.41
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer (2008) 1.37
Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene (2004) 1.29
Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res (2005) 1.21
Targeting the FLICE Inhibitory Protein (FLIP) in cancer therapy. Mol Interv (2003) 1.19
Eukaryotic initiation factor 4E. Int J Biochem Cell Biol (2007) 1.15
Translational control: a target for cancer therapy. Cancer Lett (2007) 1.11
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem (2007) 1.09
Methods for studying signal-dependent regulation of translation factor activity. Methods Enzymol (2007) 1.05
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol Cancer Ther (2007) 1.05
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res (2008) 0.99
The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther (2008) 0.94
Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling. Biochem J (2003) 0.89
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell (2011) 2.61
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res (2005) 2.43
Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin (2011) 2.42
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
Translation of innovative designs into phase I trials. J Clin Oncol (2007) 2.30
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst (2004) 2.13
Head and neck cancer chemoprevention gets a shot in the arm. J Clin Oncol (2008) 2.09
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res (2008) 2.01
Perspectives for cancer prevention with natural compounds. J Clin Oncol (2009) 1.99
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res (2006) 1.94
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer (2012) 1.94
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res (2006) 1.85
Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol (2006) 1.78
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther (2007) 1.71
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res (2005) 1.70
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res (2009) 1.70
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol (2007) 1.54
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol (2013) 1.54
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) (2011) 1.53
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest (2010) 1.50
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol (2002) 1.50
Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci U S A (2007) 1.49
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer (2004) 1.47
Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. Cancer Biol Ther (2005) 1.47
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol (2008) 1.43
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol (2011) 1.42
Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther (2007) 1.41
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem (2010) 1.40
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control (2003) 1.39
14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol (2011) 1.38
Accurate biopsy of bile duct without destroying duodenal papilla. Turk J Gastroenterol (2016) 1.37
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther (2008) 1.36
Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res (2011) 1.36
Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. Cancer (2012) 1.33
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther (2007) 1.33
Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res (2004) 1.32
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 1.32
Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol (2007) 1.31
p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res (2004) 1.30
The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem (2009) 1.30
2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther (2008) 1.29
Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci (2013) 1.29
LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res (2008) 1.28
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res (2005) 1.28
Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). Cancer Biol Ther (2006) 1.27
A novel DNMT3B subfamily, DeltaDNMT3B, is the predominant form of DNMT3B in non-small cell lung cancer. Int J Oncol (2006) 1.27
Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res (2002) 1.26
Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res (2002) 1.26
The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res (2008) 1.26
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol (2004) 1.25
Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res (2008) 1.25